Form 4: Cytokinetics Director Acquires Shares in Lieu of Cash Retainer

Robert Arthur Harrington, a director at Cytokinetics Inc, acquired 255 shares of common stock on January 2, 2025, in lieu of a cash retainer.

Summary

• On January 2, 2025, Robert Arthur Harrington, a director of Cytokinetics Inc, acquired 255 shares of common stock.
• The acquisition was made in lieu of a cash retainer, as part of the Director Stock in Lieu of Cash Retainer Program.
• The price per share was $48.93.
• Following the transaction, Harrington directly owns 16,008 shares of Cytokinetics Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction of a director receiving stock in lieu of cash, indicating alignment with shareholder interests but not necessarily a major positive or negative signal.

Positives

• Director's participation in the stock in lieu of cash retainer program demonstrates confidence in the company's future.

Industry Context

Directors receiving stock in lieu of cash compensation is a fairly common practice, especially in growth-oriented companies, as it aligns their interests with those of shareholders and conserves cash.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders as it aligns the director's interests with theirs.

Key Dates